Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
PETROCHINA
00857
No Data
Prescient Tightens Governance With Updated Securities Trading Policy
Prescient Widens Half-year Loss as R&D Spend Climbs but Bolsters Balance Sheet
Prescient Therapeutics Ltd: Appendix 4D and Half Year Financial Report
Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients With NRG1+ Non-Small Cell Lung Cancer: New Results From the ENRGy Trial
Green Canada Upsizes Financing as PTX Loses Control Ahead of MAACKK Reverse Takeover
Prescient Therapeutics Issues 21.78m Unquoted Options Under Employee Incentive Plan